Mutation-driven drug development in melanoma
KT Flaherty, FS Hodi, BC Bastian - Current opinion in oncology, 2010 - journals.lww.com
KT Flaherty, FS Hodi, BC Bastian
Current opinion in oncology, 2010•journals.lww.comLarger clinical trials are needed to fully define the efficacy of BRAF and CKIT-directed
therapy in melanoma, but early results suggest that this strategy will transform treatment
options. Additional potential targets have been identified, and clinical trials evaluating novel
drugs against them are underway.
therapy in melanoma, but early results suggest that this strategy will transform treatment
options. Additional potential targets have been identified, and clinical trials evaluating novel
drugs against them are underway.
Summary
Larger clinical trials are needed to fully define the efficacy of BRAF and CKIT-directed therapy in melanoma, but early results suggest that this strategy will transform treatment options. Additional potential targets have been identified, and clinical trials evaluating novel drugs against them are underway.
Lippincott Williams & Wilkins